Top Articles
Expect RESULTS Act Vote by End of the Year
At the Executive War College, an insider panel provides updates on thorny legislative concerns
CEO SUMMARY: Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scruti...
Examining Roche’s Deal to Acquire PathAI
Larger biopharma players are not outpacing independent digital pathology vendors
CEO SUMMARY: At first glance, Roche’s announcement that it had bought digital pathology and AI firm PathAI could be seen as a narrowing of options for clinical laboratories and pathology practices. However, insider Lisa-Jean Clifford says labs have long had access to dig...
Steep Sentence Underscores Scrutiny of Genetic Testing
Two clinical lab operators plead guilty in a case stemming from half a billion dollars in fraud
The sentencing tied to a $522 million genetic testing fraud scheme is more than just the latest fraud headline for clinical laboratory professionals. Instead, it serves as another warning that federal scrutiny surrounding genetic testing is continuing and unlikel...
Labs Looking at Cash-Based Options Face Complexity
Direct-to-consumer testing programs may need legal input to properly structure compliance
Given all the challenges of dealing with payers, many clinical laboratories find themselves tempted by the idea of offering cash-based business lines such as direct-to-consumer (DTC) testing. The patient pays up front and undergoes the test, and the lab banks the...
Astorg Makes Billion-Dollar Bet on Microbiology Testing
Sale of Thermo Fisher’s microbiology line reflects broader trend of prioritizing high-growth tests
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to ...
Behind the Cat-and-Mouse Game of Lab Reimbursement
Commercial payers use new denial tactics as clinical labs fight back with automation
Financial relationships between clinical laboratories and commercial payers have evolved into a high-stakes, technological tug-of-war. For nearly a decade, the clinical laboratory industry has wrestled with the provisions of the Protecting Acce...
Risk of Complacency May Be the Biggest Threat
Prevailing sentiment at the recent Executive War College suggests a long-overdue legislative reprieve is within r...
Don’t Be at the Mercy of the Tumultuous Healthcare Revolution
Subscribe to The Dark Report for as little as $15.27 per week.
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.